# Addressing The Gynecologic Oncology Workforce Crisis in Malawi

# Lameck Chinula, MD Obstetrician and Gynecologist

University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, USA
Kamuzu Central Hospital, Department of Obstetrics and Gynecology, Lilongwe, Malawi
College of Medicine, Department of Obstetrics & Gynecology, Blantyre, Malawi







#### Disclosures

• No financial relationships or conflicts of interest to disclose







# Background: Country profile

- Population: 18 million
  - 16.7 % urban
- Life expectancy: 54.8 years
- Poverty rate: 50.7%
- Female literacy rate: 57.2%
- National HIV prevalence: 9.1%
  - 20% among women 40-44 years [1,2]











## Background: Cervical cancer in Malawi

- #1 cause of cancer-related death
- 40% of cancer cases and 35% of cancer deaths among women
- Estimated 3,684 women diagnosed with cervical cancer each year
  - 2,314 die from the disease annually
- Age standardized incidence rate (ASR) of 75.9 per 100,000
  - Highest in the world [3]

#### Cancer Incidence



#### **Cancer Mortality**











#### Background: Cervical cancer control infrastructure

- No national HPV vaccination program
- Very low screening coverage, 9%-27% between 2011-2015. [4]
- Only 1 certified gyn oncologist in the country
- No radiation therapy
- Very limited access to chemotherapy







#### Method: Competency-based educational curriculum

- In June 2015, 2 U.S. senior GYN oncologists implemented a novel curriculum to teach Malawian gynecologists to safely and effectively perform radical hysterectomy and pelvic lymphadenectomy:
  - Self-directed learning
  - Intense 5-day practicum
  - Continued clinical mentorship through e-based communication and quarterly visits









## Training Site: Kamuzu Central Hospital

- 1,000-bed public tertiary care hospital
- Serves 7 million people throughout Central and Northern Malawi









#### Results: Surgical procedures (June 2015-Dec 2016)

- 24 patients underwent rad hyst & pelvic lymphadenectomy
  - Apprentice and Master Trainer 8
  - Apprentice alone 16
- Stage 1B1: (70%)
- Median age: 46 years (IQR 40-51 years)
- Median parity: 5 (IQR: 3-6)
- HIV positivity: (53%)

		Master Trainer & Apprentice (N=8)	Apprentice (N=16)	
Age (years)				
<b>3</b> (3 )	≤ 40 > 40	1 (12.5) 7 (87.5)	5 (31.3) 11 (68.8)	
Parity		. (5.15)	(55.5)	
,	< 5 > 5	2 (25.0) 6 (75.0)	6 (37.5) 10 (62.5)	
Marital status				
	Single Married Widowed/divorced Missing data	0 (0.0) 5 (62.5) 1 (12.5) 2 (25.0)	1 (6.3) 7 (43.8) 4 (25.0) 4 (25.0)	
HIV status	9	, ,	, ,	
	Negative Positive Missing data	2 (25.0) 3 (37.5) 3 (37.5)	6 (37.5) 6 (37.5) 4 (25.0)	
Clinical stage				
	1A2 1B1 1B2 2A1 Missing data	2 (25.0) 2 (25.0) 2 (25.0) 2 (25.0) 0 (0.0)	0 (0.0) 12 (75.0) 0 (0.0) 3 (18.8) 1 (6.3)	
Pre-operative HB				
	< 11g/dl ≥ 11g/dl Missing data	0 (0.0) 4 (50.0) 4 (50.0)	2 (12.5) 9 (56.3) 5 (31.3)	







## Results: Apprentice progression

- After intense 5 day practicum (8 cases): apprentice could safely and competently perform the surgical procedure
- At 3-month mentoring visit: apprentice independently performed the procedure on 5 cases
- At 6-month mentoring visit: apprentice began training others on 3 cases







## Results: Surgical outcomes

- Blood transfusion required in 12/16 (75%) cases, (8 had missing data)
- Parametrial involvement was histologically-confirmed in 1 of 18 cases (not reported in 6 cases)
- Intraoperative hemorrhage (1)
  - Positive pelvic lymph nodes; vascular and parametrial involvement
- Vesicovaginal fistula (1)
  - Resolved with continuous bladder drainage over 2 weeks

Section   Sec		Master Trainer & Apprentice (N=8)	Apprentice only (N=16)		
≥ 1,000         2 (25.0)         6 (37.5)           Missing data         5 (62.5)         6 (37.5)           Blood transfusion         No         2 (25.0)         2 (12.5)           Yes         2 (25.0)         10 (62.5)           Missing data         4 (50.0)         4 (25.0)           Pelvic Lymph Nodes Positive         8         1 (12.5)         3 (18.8)           No         5 (62.5)         9 (56.3)         Yes         1 (12.5)         3 (18.8)           Missing data         2 (25.0)         4 (25.0)         4 (25.0)         4 (25.0)           Vaginal Margin Negative         8 (75.0)         12 (75.0)         4 (25.0)         4 (25.0)           Vaginal Involvement Present         8 (75.0)         12 (75.0)         4 (25.0) </td <td colspan="5">Blood Loss</td>	Blood Loss				
Missing data   5 (62.5)   6 (37.5)	< 1,000	1 (12.5)	4 (25.0)		
No	≥ 1,000	2 (25.0)	6 (37.5)		
No	Missing data	5 (62.5)	6 (37.5)		
Yes         2 (25.0)         10 (62.5)           Missing data         4 (50.0)         4 (25.0)           Pelvic Lymph Nodes Positive           No         5 (62.5)         9 (56.3)           Yes         1 (12.5)         3 (18.8)           Missing data         2 (25.0)         4 (25.0)           Vaginal Margin Negative           Yes         6 (75.0)         12 (75.0)           Missing data         2 (25.0)         4 (25.0)           Parametrial Involvement Present           No         7 (88.0)         10 (62.5)           Yes         0 (0.0)         1 (6.3)           Missing data         1 (12.0)         5 (31.2)           Post-Operative Histologic Findings           No residual disease         1 (12.5)         1 (6.3)           Cervical intraepithelial neoplasia (CIN) 3         0 (0.0)         1 (6.3)           Squamous cell carcinoma         4 (50.0)         10 (62.5)           Endometriod adenocarcinoma         1 (12.5)         0 (0.0)           Missing data         2 (25.0)         3 (18.8)           Post-Operative Complications           Infection         0 (0.0)         0 (0.0)           Hemorrhage	Blood transfusion				
Missing data	No	2 (25.0)	2 (12.5)		
No	Yes	2 (25.0)	10 (62.5)		
No   5 (62.5)   9 (56.3)   Yes   1 (12.5)   3 (18.8)   Missing data   2 (25.0)   4 (25.0)	Missing data	4 (50.0)	4 (25.0)		
Yes         1 (12.5)         3 (18.8)           Missing data         2 (25.0)         4 (25.0)           Vaginal Margin Negative         Yes         6 (75.0)         12 (75.0)           Missing data         2 (25.0)         4 (25.0)           Parametrial Involvement Present           No         7 (88.0)         10 (62.5)           Yes         0 (0.0)         1 (6.3)           Missing data         1 (12.0)         5 (31.2)           Post-Operative Histologic Findings           No residual disease         1 (12.5)         1 (6.3)           Cervical intraepithelial neoplasia (CIN) 3         0 (0.0)         1 (6.3)           Microinvasive carcinoma         0 (0.0)         1 (6.3)           Squamous cell carcinoma         4 (50.0)         10 (62.5)           Endometriod adenocarcinoma         1 (12.5)         0 (0.0)           Missing data         2 (25.0)         3 (18.8)           Post-Operative Complications           Infection         0 (0.0)         0 (0.0)           Hemorrhage         0 (0.0)         1 (6.3)*           Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         0 (0.0)					
Missing data   2 (25.0)   4 (25.0)	No	5 (62.5)	9 (56.3)		
Vaginal Margin Negative         Yes         6 (75.0)         12 (75.0)           Missing data         2 (25.0)         4 (25.0)           Parametrial Involvement Present           No         7 (88.0)         10 (62.5)           Yes         0 (0.0)         1 (6.3)           Missing data         1 (12.0)         5 (31.2)           Post-Operative Histologic Findings           No residual disease         1 (12.5)         1 (6.3)           Cervical intraepithelial neoplasia (CIN) 3         0 (0.0)         1 (6.3)           Microinvasive carcinoma         0 (0.0)         1 (62.5)           Endometriod adenocarcinoma         4 (50.0)         10 (62.5)           Endometriod adenocarcinoma         1 (12.5)         0 (0.0)           Missing data         2 (25.0)         3 (18.8)           Post-Operative Complications           Infection         0 (0.0)         0 (0.0)           Hemorrhage         0 (0.0)         1 (6.3)*           Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         1 (6.3)*           Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0) </td <td>Yes</td> <td>1 (12.5)</td> <td>3 (18.8)</td>	Yes	1 (12.5)	3 (18.8)		
Yes         6 (75.0)         12 (75.0)           Missing data         2 (25.0)         4 (25.0)           Parametrial Involvement Present           No         7 (88.0)         10 (62.5)           Yes         0 (0.0)         1 (6.3)           Missing data         1 (12.0)         5 (31.2)           Post-Operative Histologic Findings           No residual disease         1 (12.5)         1 (6.3)           Cervical intraepithelial neoplasia (CIN) 3         0 (0.0)         1 (6.3)           Microinvasive carcinoma         0 (0.0)         1 (6.3)           Squamous cell carcinoma         4 (50.0)         10 (62.5)           Endometriod adenocarcinoma         1 (12.5)         0 (0.0)           Missing data         2 (25.0)         3 (18.8)           Post-Operative Complications           Infection         0 (0.0)         0 (0.0)           Hemorrhage         0 (0.0)         1 (6.3)*           Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         1 (6.3)*           Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0)	Missing data	2 (25.0)	4 (25.0)		
Missing data   2 (25.0)   4 (25.0)	Vaginal Margin Negative				
No	Yes	6 (75.0)	12 (75.0)		
No	Missing data	2 (25.0)	4 (25.0)		
Yes         0 (0.0)         1 (6.3)           Missing data         1 (12.0)         5 (31.2)           Post-Operative Histologic Findings           No residual disease         1 (12.5)         1 (6.3)           Cervical intraepithelial neoplasia (CIN) 3         0 (0.0)         1 (6.3)           Microinvasive carcinoma         0 (0.0)         1 (6.3)           Squamous cell carcinoma         4 (50.0)         10 (62.5)           Endometriod adenocarcinoma         1 (12.5)         0 (0.0)           Missing data         2 (25.0)         3 (18.8)           Post-Operative Complications           Infection         0 (0.0)         0 (0.0)           Hemorrhage         0 (0.0)         1 (6.3)*           Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         1 (6.3)*           Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0)					
Missing data	No	7 (88.0)	10 (62.5)		
No residual disease	Yes	0 (0.0)	1 (6.3)		
No residual disease	Missing data	1 (12.0)	5 (31.2)		
Cervical intraepithelial neoplasia (CIN) 3         0 (0.0)         1 (6.3)           Microinvasive carcinoma         0 (0.0)         1 (6.3)           Squamous cell carcinoma         4 (50.0)         10 (62.5)           Endometriod adenocarcinoma         1 (12.5)         0 (0.0)           Missing data         2 (25.0)         3 (18.8)           Post-Operative Complications           Infection         0 (0.0)         0 (0.0)           Hemorrhage         0 (0.0)         1 (6.3)*           Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         1 (6.3)*           Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0)	Post-Operative Histologic Findings				
Microinvasive carcinoma         0 (0.0)         1 (6.3)           Squamous cell carcinoma         4 (50.0)         10 (62.5)           Endometriod adenocarcinoma         1 (12.5)         0 (0.0)           Missing data         2 (25.0)         3 (18.8)           Post-Operative Complications           Infection         0 (0.0)         0 (0.0)           Hemorrhage         0 (0.0)         1 (6.3)*           Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         1 (6.3)*           Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0)	No residual disease	1 (12.5)	1 (6.3)		
Squamous cell carcinoma         4 (50.0)         10 (62.5)           Endometriod adenocarcinoma         1 (12.5)         0 (0.0)           Missing data         2 (25.0)         3 (18.8)           Post-Operative Complications           Infection         0 (0.0)         0 (0.0)           Hemorrhage         0 (0.0)         1 (6.3)*           Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         1 (6.3)*           Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0)	Cervical intraepithelial neoplasia (CIN)	0 (0.0)	1 (6.3)		
Endometriod adenocarcinoma         1 (12.5)         0 (0.0)           Missing data         2 (25.0)         3 (18.8)           Post-Operative Complications           Infection         0 (0.0)         0 (0.0)           Hemorrhage         0 (0.0)         1 (6.3)*           Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         1 (6.3)*           Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0)	Microinvasive carcinoma	0 (0.0)	1 (6.3)		
Missing data         2 (25.0)         3 (18.8)           Post-Operative Complications           Infection         0 (0.0)         0 (0.0)           Hemorrhage         0 (0.0)         1 (6.3)*           Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         1 (6.3)*           Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0)	Squamous cell carcinoma	4 (50.0)	10 (62.5)		
Post-Operative Complications           Infection         0 (0.0)         0 (0.0)           Hemorrhage         0 (0.0)         1 (6.3)*           Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         1 (6.3)*           Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0)	Endometriod adenocarcinoma	1 (12.5)	0 (0.0)		
Infection         0 (0.0)         0 (0.0)           Hemorrhage         0 (0.0)         1 (6.3)*           Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         1 (6.3)*           Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0)	Missing data	2 (25.0)	3 (18.8)		
Hemorrhage       0 (0.0)       1 (6.3)*         Venous thromboembolism       0 (0.0)       0 (0.0)         Urologic injury       0 (0.0)       1 (6.3)*         Vascular injury       0 (0.0)       0 (0.0)         Intestinal injury       0 (0.0)       0 (0.0)	Post-Operative Complications				
Venous thromboembolism         0 (0.0)         0 (0.0)           Urologic injury         0 (0.0)         1 (6.3)*           Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0)	Infection	0 (0.0)	0 (0.0)		
Urologic injury       0 (0.0)       1 (6.3)*         Vascular injury       0 (0.0)       0 (0.0)         Intestinal injury       0 (0.0)       0 (0.0)	Hemorrhage	0 (0.0)	1 (6.3) <sup>1</sup>		
Vascular injury         0 (0.0)         0 (0.0)           Intestinal injury         0 (0.0)         0 (0.0)	Venous thromboembolism	0 (0.0)	0 (0.0)		
Intestinal injury 0 (0.0) 0 (0.0)	Urologic injury	0 (0.0)	1 (6.3)*		
	Vascular injury	0 (0.0)	0 (0.0)		
*Vesicovaginal fistula diagnosed at day 10 post op; resolved with continuous catheterization.	Intestinal injury	0 (0.0)	0 (0.0)		
Hemorrhage: lost 4,000 ml of blood intraoperatively					







#### Discussion

- Teaching a <u>limited repertoire of oncologic surgical procedures</u> targeting cancers that are both common and amenable to surgical cure
  - rapidly builds local surgical oncologic capacity
  - saves lives
  - can sustain and reproduce itself within the reality of its context
- Ancillary support such as adequate supply of blood, anesthesia, is critical to ensure patient safety
- This training approach can complement ongoing international efforts to expand formal gynecologic oncology training opportunities to physicians practising in LMICs







## Challenges and Future Directions

- Scaling this training approach through a regional center of excellence
- Adding other relevant surgical procedures, e.g., radical vulvectomy and inguinofemoral lymphadenectomy
- Recruiting additional surgical mentors who have the surgical skills to perform open procedures and to operate on large lesions
- Improving pathology support







#### References

- 1. Malawi Demographic and Health Survey. National Statistical Office, Zomba, Malawi, ICF Macro Calverton, Maryland, USA. September 2011.
- 2. 2015-16 Demographic and Health Survey. HIV Prevalence Fact Sheet. Malawi
- 3. International Agency for Research on Cancer (IARC), World Health Organization (WHO). GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012: cancer fact sheets: cervical cancer. Lyon: IARC; 2014
- 4. Msyamboza KS et al. Cervical cancer screening uptake and challenges in Malawi from 2011 to 2015: retrospective cohort study. BMC Public Health (2016) 16:806. DOI 10.1186/s12889-016-3530-y







#### Acknowledgements

- Groesbeck Parham, MD, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Obstetrics and Gynecology, University Teaching Hospital, Lusaka, Zambia
- Michael Hicks, MD, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Obstetrics and Gynecology, University Teaching Hospital, Lusaka, Zambia
- Grace Chiudzu, MD, Department of Obstetrics and Gynecology, Kamuzu Central Hospital, Lilongwe, Malawi
- Jennifer Tang MD, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Satish Gopal MD, Lineberger Comprehensive Cancer Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Medical Education Partnership Initiative (MEPI), R24 TW008927-01





